Profil:
Sopharma ADSOPHARMA AD (3/2025) Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212
Report no 3/2025
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
"Sopharma" AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that in pursuance of a decision of the Board of Directors of SOPHARMA AD from October 14, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art. 25 of the Articles of incorporation of the company a procedure for capital increase was launched for issuing up to 623 779 ordinary registered dematerialized freely transferable shares with a nominal value of BGN 1 each and issue value of BGN 4.13 for one share, under the condition that the shares of the increase are subscribed by the holders of warrants of issue with ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for Public Offering of Warrants, confirmed by a Decision of the Financial Supervision Commission (FSC) No 804-E/ 04.11.2021.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz